Clin Drug Investig (2017) 37:833–844 DOI 10.1007/s40261-017-0540-1 ORIGINAL RESEARCH ARTICLE Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece 1 2 3 4 • • • • George Gourzoulidis Georgia Kourlaba John Kakisis Mitiadis Matsagkas 5 6 7 • • • George Giannakoulas Konstantinos I. Gourgoulianis Theodoros Vassilakopoulos Nikos Maniadakis Published online: 12 June 2017 Springer International Publishing Switzerland 2017 Abstract with enoxaparin followed by dose-adjusted vitamin-K Background and Objective Venous thromboembolism antagonists for the treatment of DVT and PE in Greece. (VTE), comprising deep-vein thrombosis (DVT) and pul- Methods An existing Markov model was locally adapted monary embolism (PE), is a major healthcare concern that from a third-party payer perspective to reﬂect the man- results in substantial morbidity and mortality with great agement and complications of DVT and PE in the course of economic burden for healthcare systems. Hence, the need 3-month cycles, up to death. The clinical inputs and utility for effective and efﬁcient treatment of patients with VTE is values were extracted from published studies. Direct important for both clinical and economic reasons. The medical costs, obtained from local resources, were incor- objective of this study was to evaluate the
Clinical Drug Investigation – Springer Journals
Published: Jun 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud